Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

She’s had two healthy pregnancies since undergoing the trial, which uses modified white blood cells to attack cancer cells.

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

CAR-T cell therapy achieves 18-year survival milestone in cancer patient Innovative cancer treatment shows promise as ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

The NHS says it already offers some CAR-T therapies and is consulting on "potential future treatments". Only this week, the National Institute for Health and Care Excellence has recommended the use of ...

Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...